©2022 Stanford Medicine
Long-term Cognitive, Neuropsychiatric and Functional Outcomes in Adults Who Have Received Chimeric Antigen-Receptor T-Cell (CAR-T) Therapy for Aggressive Lymphoma at Stanford
Not Recruiting
Trial ID: NCT05416554
Purpose
This study aims to assess the feasibility of performing neuropsychological testing to measure
the cognitive performance of individuals following Axicabtagene ciloleucel CAR-T therapy at
Stanford.
Official Title
Long-term Cognitive, Neuropsychiatric and Functional Outcomes in Adults Who Have Received Chimeric Antigen-Receptor T-Cell (CAR-T) Therapy for Aggressive Lymphoma at Stanford - A Pilot Study
Stanford Investigator(s)
Brian J Scott
Clinical Professor, Neurology & Neurological Sciences Clinical Associate Professor (By courtesy), Neurosurgery
Matthew Frank
Assistant Professor of Medicine (Blood and Marrow Transplantation and Cellular Therapy)
Eligibility
Inclusion Criteria:
- >/= 18 years-old
- Treated with Axicabtagene ciloleucel CAR-T therapy at Stanford Or
- Treated with standard commercial Axicabtagene ciloleucel CAR-T therapy elsewhere and
followed primarily by SHC Blood and Bone Marrow transplant providers
- >/= 6 months from the date of CAR-T infusion
- Fluent in English
- Able to attend and participate in in-person testing (Arm I)
- Able to participate in remote video testing with adequate workspace, computer and
internet capabilities for a reliable telehealth video connection (Arm II)
Exclusion Criteria:
- Concurrent enrollment in a CAR-T therapeutics research study
- Unable to be present for the scheduled testing
- Unable to participate in testing due to severe cognitive or physical limitation
- Actively receiving chemotherapy
- Progressive cancer
Intervention(s):
behavioral: Neuropsychological testing
Not Recruiting
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Brian J Scott, MD
bjscott@stanford.edu